Sectors & Industries HealthcareDiagnostics & Research
Best Diagnostic & Research Stocks to Buy Now (2026)
Top diagnostic & research stocks in 2026 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best diagnostic & research stocks to buy now. Learn More.

Industry: Diagnostics & Research

Zen Rating Price Value Growth Financials Momentum Sentiment Forecast Dividends Due Diligence

Diagnostics & Research is Zen Rated B and is the 30th ranked industry out of 145 stock market industries

Ticker	Company	Exchange	Industry	Market Cap	Price	1d %	EBITDA	P/E	D/E	Country
ILMN	ILLUMINA INC	NASDAQ	Diagnostics & Research	$20.56B	$134.46	5.54%	$1.46B	24.58x	1.44	United States
SHC	SOTERA HEALTH CO	NASDAQ	Diagnostics & Research	$4.62B	$16.25	-1.34%	$439.93M	60.19x	4.38	United States
IDXX	IDEXX LABORATORIES INC	NASDAQ	Diagnostics & Research	$52.29B	$656.73	-0.60%	$1.51B	49.87x	1.09	United States
A	AGILENT TECHNOLOGIES INC	NYSE	Diagnostics & Research	$34.41B	$121.38	0.34%	$1.84B	26.44x	0.89	United States
RVTY	REVVITY INC	NYSE	Diagnostics & Research	$10.99B	$98.31	-0.71%	$763.29M	47.49x	0.68	United States
LH	LABCORP HOLDINGS INC	NYSE	Diagnostics & Research	$23.82B	$289.12	0.52%	$2.22B	27.43x	1.13	United States
TMO	THERMO FISHER SCIENTIFIC INC	NYSE	Diagnostics & Research	$193.58B	$521.11	0.19%	$11.45B	29.33x	1.07	United States
MEDP	MEDPACE HOLDINGS INC	NASDAQ	Diagnostics & Research	$12.82B	$451.76	1.04%	$580.74M	28.88x	3.30	United States
MTD	METTLER TOLEDO INTERNATIONAL INC	NYSE	Diagnostics & Research	$27.78B	$1,366.69	-0.76%	$1.24B	32.41x	-158.08	United States
NEOG	NEOGEN CORP	NASDAQ	Diagnostics & Research	$2.44B	$11.23	-0.80%	-$427.52M	-4.05x	0.60	United States
BNR	BURNING ROCK BIOTECH LTD	NASDAQ	Diagnostics & Research	$278.30M	$25.83	8.26%	N/A	-15.72x	0.48	China
DHR	DANAHER CORP	NYSE	Diagnostics & Research	$148.95B	$210.64	0.61%	$6.96B	41.55x	0.59	United States
QGEN	QIAGEN NV	NYSE	Diagnostics & Research	$10.84B	$49.80	1.47%	$717.27M	25.67x	0.67	Netherlands
IQV	IQVIA HOLDINGS INC	NYSE	Diagnostics & Research	$30.34B	$178.81	4.79%	$3.49B	22.61x	3.59	United States
PRPO	PRECIPIO INC	NASDAQ	Diagnostics & Research	$42.19M	$24.08	-0.88%	$490.00k	-29.01x	0.54	United States
DGX	QUEST DIAGNOSTICS INC	NYSE	Diagnostics & Research	$23.28B	$211.91	0.38%	$2.14B	23.89x	1.26	United States
CAI	CARIS LIFE SCIENCES INC	NASDAQ	Diagnostics & Research	$5.68B	$20.14	4.68%	N/A	N/A	1.06	United States
WAT	WATERS CORP	NYSE	Diagnostics & Research	$31.33B	$319.38	-1.07%	$1.03B	29.57x	0.98	United States
NTRA	NATERA INC	NASDAQ	Diagnostics & Research	$29.49B	$208.04	-3.73%	-$200.34M	-136.87x	0.40	United States
CDNA	CAREDX INC	NASDAQ	Diagnostics & Research	$960.82M	$18.76	-0.32%	-$9.84M	-46.90x	0.36	United States
MYGN	MYRIAD GENETICS INC	NASDAQ	Diagnostics & Research	$431.07M	$4.61	-5.14%	-$323.20M	-1.17x	0.92	United States
BLLN	BILLIONTOONE INC	NASDAQ	Diagnostics & Research	$3.49B	$76.33	6.89%	N/A	N/A	-0.62	United States
CRL	CHARLES RIVER LABORATORIES INTERNATIONAL INC	NYSE	Diagnostics & Research	$8.79B	$178.49	1.73%	$408.66M	-61.34x	1.24	United States
NEO	NEOGENOMICS INC	NASDAQ	Diagnostics & Research	$1.28B	$9.83	-3.34%	-$31.94M	-11.70x	0.63	United States
ICLR	ICON PLC	NASDAQ	Diagnostics & Research	$8.26B	$108.14	1.89%	$1.21B	14.57x	0.77	Ireland
FLGT	FULGENT GENETICS INC	NASDAQ	Diagnostics & Research	$478.77M	$15.33	-38.09%	-$42.95M	-7.78x	0.10	United States
CSTL	CASTLE BIOSCIENCES INC	NASDAQ	Diagnostics & Research	$879.15M	$29.57	-7.25%	$11.34M	-35.63x	0.23	United States
BDSX	BIODESIX INC	NASDAQ	Diagnostics & Research	$151.13M	$15.33	7.81%	-$21.88M	-3.28x	-36.49	United States
RDNT	RADNET INC	NASDAQ	Diagnostics & Research	$5.39B	$69.81	-3.16%	$268.98M	-410.65x	2.22	United States
MYNZ	MAINZ BIOMED NV	NASDAQ	Diagnostics & Research	$3.11M	$0.76	3.12%	-$18.40M	-0.14x	2.89	Germany
GRAL	GRAIL INC	NASDAQ	Diagnostics & Research	$2.08B	$53.23	-8.38%	-$388.10M	-4.99x	0.16	United States
ACRS	ACLARIS THERAPEUTICS INC	NASDAQ	Diagnostics & Research	$310.95M	$2.87	-8.31%	-$64.47M	-5.42x	0.56	United States
TWST	TWIST BIOSCIENCE CORP	NASDAQ	Diagnostics & Research	$2.88B	$46.92	-3.67%	-$50.92M	-36.94x	0.40	United States
XGN	EXAGEN INC	NASDAQ	Diagnostics & Research	$82.04M	$3.62	-4.74%	-$12.56M	-3.93x	2.46	United States
PRE	PRENETICS GLOBAL LTD	NASDAQ	Diagnostics & Research	$271.14M	$16.91	-5.05%	-$54.50M	-4.07x	0.17	Hong Kong
IMDX	INSIGHT MOLECULAR DIAGNOSTICS INC	NASDAQ	Diagnostics & Research	$172.27M	$6.01	6.00%	-$58.47M	-1.88x	-5.78	United States
GH	GUARDANT HEALTH INC	NASDAQ	Diagnostics & Research	$12.32B	$93.90	-4.15%	-$373.91M	-28.28x	-21.28	United States
LAB	STANDARD BIOTOOLS INC	NASDAQ	Diagnostics & Research	$434.56M	$1.13	-3.42%	-$107.13M	-3.42x	0.35	United States
OPK	OPKO HEALTH INC	NASDAQ	Diagnostics & Research	$921.24M	$1.20	0.00%	-$41.30M	-4.00x	0.52	United States
MDXH	MDXHEALTH SA	NASDAQ	Diagnostics & Research	$16.83M	$3.40	-4.23%	-$5.20M	-0.51x	-13.23	Belgium
STIM	NEURONETICS INC	NASDAQ	Diagnostics & Research	$91.77M	$1.34	-5.63%	-$33.50M	-1.61x	4.17	United States
PSNL	PERSONALIS INC	NASDAQ	Diagnostics & Research	$947.96M	$9.06	0.33%	-$69.66M	-9.96x	0.28	United States
FONR	FONAR CORP	NASDAQ	Diagnostics & Research	$121.93M	$18.60	0.16%	$15.32M	16.17x	0.31	United States
MBAI	CHECK-CAP LTD	NASDAQ	Diagnostics & Research	$247.70M	$1.63	-0.61%	N/A	-0.51x	0.16	Israel
NDRA	ENDRA LIFE SCIENCES INC	NASDAQ	Diagnostics & Research	$4.84M	$4.15	5.87%	-$7.84M	0.21x	10.46	United States
ISPC	ISPECIMEN INC	NASDAQ	Diagnostics & Research	$2.44M	$0.25	-9.09%	-$9.69M	-0.03x	1.93	United States
EXAS	EXACT SCIENCES CORP	NASDAQ	Diagnostics & Research	$19.73B	$103.38	0.13%	$84.09M	-93.98x	1.44	United States
NOTV	INOTIV INC	NASDAQ	Diagnostics & Research	$9.32M	$0.27	-0.73%	$23.78M	-0.14x	5.74	United States
XWEL	XWELL INC	NASDAQ	Diagnostics & Research	$8.59M	$1.49	9.56%	-$13.29M	-0.44x	-2.90	United States
SERA	SERA PROGNOSTICS INC	NASDAQ	Diagnostics & Research	$88.38M	$2.29	0.00%	-$31.13M	-2.97x	0.32	United States
TRIB	TRINITY BIOTECH PLC	NASDAQ	Diagnostics & Research	$13.30M	$0.72	0.00%	-$22.42M	-0.48x	-3.01	Ireland
VNRX	VOLITIONRX LTD	NYSEMKT	Diagnostics & Research	$26.16M	$0.21	-9.36%	-$21.14M	-0.93x	-1.22	United States
BIAF	BIOAFFINITY TECHNOLOGIES INC	NASDAQ	Diagnostics & Research	$4.77M	$1.06	1.92%	-$14.11M	-0.05x	0.30	United States
DRIO	DARIOHEALTH CORP	NASDAQ	Diagnostics & Research	$81.02M	$11.97	6.59%	-$36.24M	-1.07x	0.57	Israel
BNBX	BNB PLUS CORP	NASDAQ	Diagnostics & Research	$3.87M	$0.71	-6.33%	-$31.42M	-0.00x	0.12	United States
ADVB	ADVANCED BIOMED INC	NASDAQ	Diagnostics & Research	$4.40M	$4.06	1.30%	$4.56M	1.07x	0.14	United States

Diagnostic & Research Stocks FAQ

What are the best diagnostic & research stocks to buy right now in Mar 2026?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best diagnostic & research stocks to buy right now are:

1. Illumina (NASDAQ:ILMN)

Illumina (NASDAQ:ILMN) is the #1 top diagnostic & research stock out of 56 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Illumina (NASDAQ:ILMN) is: Value: B, Growth: C, Momentum: C, Sentiment: B, Safety: B, Financials: A, and AI: B.

Illumina (NASDAQ:ILMN) has a Due Diligence Score of 37, which is 10 points higher than the diagnostic & research industry average of 27.

ILMN passed 12 out of 33 due diligence checks and has average fundamentals. Illumina has seen its stock return 51.13% over the past year, overperforming other diagnostic & research stocks by 40 percentage points.

Illumina has an average 1 year price target of $138.60, an upside of 3.08% from Illumina's current stock price of $134.46.

Illumina stock has a consensus Buy recommendation according to Wall Street analysts. Of the 10 analysts covering Illumina, 30% have issued a Strong Buy rating, 10% have issued a Buy, 50% have issued a hold, while 0% have issued a Sell rating, and 10% have issued a Strong Sell.

2. Sotera Health Co (NASDAQ:SHC)

Sotera Health Co (NASDAQ:SHC) is the #2 top diagnostic & research stock out of 56 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Sotera Health Co (NASDAQ:SHC) is: Value: C, Growth: C, Momentum: C, Sentiment: C, Safety: B, Financials: B, and AI: C.

Sotera Health Co (NASDAQ:SHC) has a Due Diligence Score of 30, which is 3 points higher than the diagnostic & research industry average of 27.

SHC passed 10 out of 33 due diligence checks and has average fundamentals. Sotera Health Co has seen its stock return 32.33% over the past year, overperforming other diagnostic & research stocks by 21 percentage points.

Sotera Health Co has an average 1 year price target of $21.40, an upside of 31.69% from Sotera Health Co's current stock price of $16.25.

Sotera Health Co stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 5 analysts covering Sotera Health Co, 60% have issued a Strong Buy rating, 20% have issued a Buy, 20% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Idexx Laboratories (NASDAQ:IDXX)

Idexx Laboratories (NASDAQ:IDXX) is the #3 top diagnostic & research stock out of 56 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year. Learn more.

The Component Grade breakdown for Idexx Laboratories (NASDAQ:IDXX) is: Value: C, Growth: C, Momentum: C, Sentiment: B, Safety: C, Financials: A, and AI: B.

Idexx Laboratories (NASDAQ:IDXX) has a Due Diligence Score of 53, which is 26 points higher than the diagnostic & research industry average of 27.

IDXX passed 18 out of 33 due diligence checks and has strong fundamentals. Idexx Laboratories has seen its stock return 48.91% over the past year, overperforming other diagnostic & research stocks by 38 percentage points.

Idexx Laboratories has an average 1 year price target of $765.71, an upside of 16.59% from Idexx Laboratories's current stock price of $656.73.

Idexx Laboratories stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 7 analysts covering Idexx Laboratories, 71.43% have issued a Strong Buy rating, 0% have issued a Buy, 28.57% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the diagnostic & research stocks with highest dividends?

Out of 6 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

1. Quest Diagnostics (NYSE:DGX)

Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 1.51%, which is 1 percentage points higher than the diagnostic & research industry average of 0.72%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 36.1% indicates that its dividend yield is sustainable for the long-term.

2. Agilent Technologies (NYSE:A)

Agilent Technologies (NYSE:A) has an annual dividend yield of 0.82%, which is the same as the diagnostic & research industry average of 0.72%. Agilent Technologies's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Agilent Technologies's dividend has shown consistent growth over the last 10 years.

Agilent Technologies's dividend payout ratio of 21.6% indicates that its dividend yield is sustainable for the long-term.

3. Labcorp Holdings (NYSE:LH)

Labcorp Holdings (NYSE:LH) has an annual dividend yield of 0.75%, which is the same as the diagnostic & research industry average of 0.72%. Labcorp Holdings's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Labcorp Holdings's dividend has not shown consistent growth over the last 10 years.

Labcorp Holdings's dividend payout ratio of 27.3% indicates that its dividend yield is sustainable for the long-term.

Why are diagnostic & research stocks down?

Diagnostic & research stocks were down -0.22% in the last day, and up 0.66% over the last week. Fulgent Genetics was the among the top losers in the diagnostics & research industry, dropping -38.09% yesterday.

Fulgent Genetics shares are trading lower after the company reported mixed Q4 financial results. The company also issued FY26 guidance below estimates.

What are the most undervalued diagnostic & research stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued diagnostic & research stocks right now are:

1. Icon (NASDAQ:ICLR)

Icon (NASDAQ:ICLR) is the most undervalued diagnostic & research stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Icon has a valuation score of 100, which is 84 points higher than the diagnostic & research industry average of 16. It passed 7 out of 7 valuation due diligence checks.

Icon's stock has dropped -42.97% in the past year. It has underperformed other stocks in the diagnostic & research industry by -54 percentage points.

2. Qiagen Nv (NYSE:QGEN)

Qiagen Nv (NYSE:QGEN) is the second most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Qiagen Nv has a valuation score of 29, which is 13 points higher than the diagnostic & research industry average of 16. It passed 2 out of 7 valuation due diligence checks.

Qiagen Nv's stock has gained 29.69% in the past year. It has overperformed other stocks in the diagnostic & research industry by 19 percentage points.

3. Revvity (NYSE:RVTY)

Revvity (NYSE:RVTY) is the third most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Revvity has a valuation score of 29, which is 13 points higher than the diagnostic & research industry average of 16. It passed 2 out of 7 valuation due diligence checks.

Revvity's stock has dropped -10.99% in the past year. It has underperformed other stocks in the diagnostic & research industry by -22 percentage points.

Are diagnostic & research stocks a good buy now?

50% of diagnostic & research stocks rated by analysts are a strong buy right now. On average, analysts expect diagnostic & research stocks to rise by 20.09% over the next year.

4.76% of diagnostic & research stocks have a Zen Rating of A (Strong Buy), 28.57% of diagnostic & research stocks are rated B (Buy), 64.29% are rated C (Hold), 2.38% are rated D (Sell), and 0% are rated F (Strong Sell).

What is the average p/e ratio of the diagnostics & research industry?

The average P/E ratio of the diagnostics & research industry is 16.26x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.